Mehdi Mirsaeidi, MD, MPH, Director of the ILD and Sarcoidosis Program at the Jacksonville College of Medicine, joins Lungcast to review the rare disease for Sarcoid Awareness Month.
0:16 The history of sarcoidosis
1:54 Introducing Mehdi Mirsaeidi, MD, MPH
2:54 Understanding inflammatory process in sarcoidosis
5:01 How advanced sarcoidosis presents in clinics
8:34 Anti-inflammatories for sarcoidosis
12:10 The role of lung transplantation
14:27 COVID-19 complications among patients
16:42 The sarcoidosis specialty care team
18:13 Clinical research endeavors
19:36 Outro
Despite being a rare disease with still little-understood pathophysiology, sarcoidosis is a generally tenable disease among afflicted patients. However, there is risk of pulmonary manifestations putting patients at increased likelihood of severe respiratory disease or even death.
Modern research into sarcoidosis spans from interpreting inflammatory pathways that result in severe disease, to reviewing the viability of targeting agents and invasive care alike. And with April being Sarcoidosis Awareness Month, there’s no better time to learn more about the details into these endeavors and more.
Mehdi Mirsaeidi, MD, MPH, Director of the ILD and Sarcoidosis Program at the Jacksonville College of Medicine, joins the April 2022 episode of Lungcast to discuss the state of pulmonary sarcoidosis clinical discussion and ambitions of research.
Throughout the discussion, he and American Lung Association (ALA) Chief Medical Officer Albert Rizzo, MD, discuss the intricacies of care surrounding the rare disease—from lung transplant recommendations, to advanced sarcoidosis manifestations, to the impact of COVID-19 on infected patients.
Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.
Subscribe or listen to Lungcast on your favorite platforms:
